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1. Introduction 
The Human papillomavirus (HPV) is etiologically related to the development of uterine 
cervical and other genital cancers (Bosch et al., 1995; Frisch et al., 1999; Melbye & Frisch, 
1998), and may be involved also in the etiology of cancers of the upper aerodigestive tract 
comprising the head and neck (HN) tumors (Franceschi et al., 1996). Some molecular and 
epidemiological studies support such possibility, once that an increased risk of cancer of the 
oral cavity, pharynx and larynx subsequent to the occurrence of cancer of the cervix has 
been found. Moreover, the incidence of some head and neck tumors has been increasing 
around the world and this high prevalence was attributed to the influence of risk factors, 
being the human papillomavirus important in this role.  
The present chapter aims at investigating epidemiologic features of HPV in head and neck 
cancer worldwide in order to determine the prevalence and the type distribution of HPV by 
means of a literature review of published studies. 
2. Epidemiology of head and neck cancer 
The head and neck cancer comprises malignancies arising in the upper respiratory and 
digestive tracts and is a relatively frequent type of cancer (Parkin et al., 2002). Thus, the term 
“head and neck cancer” includes lesions at several anatomic sites, such as the lip, oral 
cavity, nose and paranasal sinuses, naso-pharynx, oro-pharynx, hypo-pharynx, larynx, 
oesophagus, salivary glands, as well the soft tissues of the neck and ear. Unfortunately, 
many papers lack the exact location of the head and neck lesions, making the material 
poorly characterised. The human papillomavirus (HPV) detection rates reported in the so-
called head and neck cancer do not give us a detailed view of the association of HPV in 
distinct entities, unless detailed anatomic locations are given (Syrjänen, 2005).  
The malignant tumors of the head and neck consist of a rather heterogeneous group of 
neoplasias arising in the epithelium of the upper aerodigestive tract. The most common 
histologic type is squamous cell carcinomas (SCC), occurring in the oral cavity, pharynx 
(nasopharynx, oropharynx and hypopharynx) and larynx (Lassen, 2010).  
Worldwide annually, over 650,000 patients are diagnosed with HNSCC and some 350,000 
die from this disease every year (Ferlay et al., 2010; Syrjänen, 2010). Head and neck cancer is 
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the sixth most common cancer worldwide (Parkin et al., 2002), and the table 1 summarizes 
the global incidence and mortality of head and neck cancer per anatomic site. 
CANCER INCIDENCE MORTALITY 
Oral cavity and lip 
Male 170,496 83,109 
Female 92,524 44,545 
Total 263,020 127,654 
Nasopharynx 
Male 57,852 35,984 
Female 26,589 15,625 
Total 84,441 51,609 
Other pharynx 
Male 108,588 76,458 
Female 28,034 19,092 
Total 136,622 95,550 
Larynx 
Male 129,651 70,336 
Female 21,026 11,556 
Total 150,677 81,892 
Table 1. Global incidence and mortality of head and neck cancer per anatomic site (Ferlay et 
al., 2010). GLOBOCAN (IARC). 
The rates of incidence and mortality around the world of head and neck squamous cell 
carcinomas have been broadly varying, with notably high rates in Southeast Asia and 
Eastern Europe (Franceschi et al., 1996). In addition, there is a considerable global variation 
in the incidence of the disease due to geographic differences in ethnicity, culture and socio-
economics (Lassen, 2010). Figure 1, obtained through the Globocan project (Ferlay et al., 
2010) illustrates the global incidence of head and neck cancer. 
Incidence and survival trends have recently been reported in various types of cancer based 
on 1994–2003 data from cancer registries in a large number of European countries. Oral 
cavity and pharyngeal cancer were analysed as a group and divergent incidence trends were 
observed when different countries were compared. For some countries, there was an 
increase in incidence (England, Wales and Czech Republic), whereas for other countries 
there was no change (a.o. Switzerland and Denmark) or a decrease (a.o. Finland, France and 
Germany) (Karim et al., 2008). 
Jemal et al. (2008) estimated that 47,500 people were diagnosed with head and neck cancer 
in the United States, representing approximately 3% of new cancer diagnoses, and an 
estimated 11,260 people died from this disease, with squamous cell carcinomas in the 
majority of these cases. 
Shiboski et al. (2005) showed, with an analysis of the National Cancer Institute’s 
Surveillance, Epidemiology and End Results (SEER) data from 1973-2001, an annual increase 
in the incidence of oral tongue, palatine tonsil, and base-of-tongue cancers, by 2.1%, 3.9%, 
and 1.7%, respectively, in 20- to 44-year-old white patients, while the incidence of HNSCC at 
other sites declined. 
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Fig. 1. Global incidence of head and neck tumors (oral cavity and lip, larynx, nasopharynx 
and other pharynx). Estimated age-standardized incidence rate per 100,000, both sexes, all 
ages (Ferlay et al., 2010). GLOBOCAN (IARC). 
3. Head and neck cancer and HPV 
Since the first description of a potential link between HPV infection and head and neck 
cancer (Syrjänen, 1984), several studies have strongly supported an etiologic role for HPV in 
cancers arising from specific mucosal sites within the head and neck (D’Souza et al., 2007; 
Gillison et al., 2000; Herrero et al., 2003). Thus, the detection of HPV genomic 
deoxyribonucleic acid (DNA) has been found in approximately 25.9% of 5,046 HNSCC 
cancer specimens from 60 studies using sensitive polymerase chain reaction–based methods 
(Kreimer et al., 2005). 
Head and neck squamous cell carcinoma (HNSCC) typically affects male smokers older than 
55 years.  Recently, an increase in the incidence of HNSCC in young adults has been 
recognized, many of them nonsmokers and females. Functional inactivation of p16 is known 
to be a common event in HNSCC, mainly by either deletion or epigenetic changes. A 
previous study by this group has shown that p16 deletions in HNSCC are significantly 
associated with age. The primary objective of this study was to evaluate additional 
molecular alterations of p16 in HNSCC, specifically in relation to age, site, and human 
papillomavirus (HPV) status. Patients ranging in age from 22 to 76 years with HNSCC were 
prospectively identified (n = 24). Methylation-specific polymerase chain reaction and 
immunohistochemistry were used to evaluate p16 gene inactivation and p16 protein 
expression, respectively. HPV 16 status was determined for each case. Overall, p16 
inactivation was a frequent event detected in 46% of cases. Methylation of p16 was more 
often detected in females than males (P = .05). All cases showing p16 methylation were from 
the anterior tongue, and 75% of them were young patients. The results indicate that p16 
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methylation is a more common event in those younger than 40 years in contrast to p16 
deletions, which are more common in those older than 40 years. Consequently, it appears 
that specific modes of inactivation of p16 in HNSCC are related to specific patient risk 
profiles. Interestingly, HPV 16 messenger RNA was detected exclusively in HNSCC from 
the base of tongue lesions and was only found in males. This differs from the patient profile 
of HNSCC in the young, which affects the anterior tongue and commonly females, thus, 
making it highly unlikely that this virus is a primary causative agent of HNSCC in these 
young adults (O'Regan et al., 2008). 
Despite successful efforts to control tobacco and alcohol consumption in the western world, 
several developed countries report rising oropharyngeal squamous cell carcinoma (OPSCC) 
incidence figures, specifically in young individuals. Similar to anogenital cancers, a 
significant proportion of OPSCC (up to 60%) is caused by sexually acquired HPV infection 
and the rise in OPSCC has been attributed to changing sexual behaviours in the Western 
World. Accordingly, patients with HPV-positive OPSCC report divergent sexual histories 
and absence of classical risk factors as tobacco and alcohol exposure compared to patients 
with HPV-negative OPSCC. The profile of HPV-positive OPSCC differs from HPV-negative 
OPSCC in several other significant aspects, including a unique molecular biologic tumor 
characteristics and improved clinical behaviour. Thus, a further increase in HPV-positive 
OPSCC will impact significantly upon clinical management of OPSCC, unless it is halted by 
adequate preventive measures aimed at reduction of HPV-associated disease. HPV 
vaccination has been recently offered to young females in an attempt to reduce HPV-
induced cervical cancer and may ultimately result in a decline of OPSCC incidence as well. 
Until then, close collaboration between otolaryngologists/head and neck surgeons and 
anogenital/genitourinary specialists is warranted to optimize clinical management of HPV-
induced malignancy and improve detection of second primary tumor development (Monsj 
et al., 2010). 
In addition, some researches revealed differences between positive and negative tumors for 
human papillomavirus being the HPV-positive HNSCC patients approximately 5 years 
younger than HPV-negative HNSCC patients with equal distribution between the sexes 
(Haraf et al., 1996; Cruz et al., 1996; Sisk et al., 2002; Strome et al., 2002). For a better 
understanding, although the epidemiology of HPV in head and neck cancer is the aim in 
this chapter, a brief explanation on the risk factors in HPV infection is necessary before 
beginning this approach. 
3.1 Risk factors 
Over the last two decades, biological agents have been implicated in the etiology of this tumor. 
Among these agents, human papillomavirus (HPV) is particularly important (Badaracco et 
al.,2000;  Cortezzi et al., 2004; Lo Muzio et al., 2004;  Smith  et al., 2004; Ibieta et al., 2005). HPV 
is a DNA virus which encodes two oncoproteins that play an important role in carcinogenesis, 
i.e., E6 which binds, sequesters and degrades p53, and E7 which binds and degrades pRb; thus 
facilitating the development of tumors (Badaracco et al.,2000; Cortezzi et al., 2004; Lo Muzio et 
al., 2004; Remmerbach et al., 2004). Although the relationship between this virus and 
malignant uterine cervix tumors has been well established in the literature, with more than 
90% of these tumors being positive for the virus, the same does not apply to oral 
carcinogenesis (Miller  et al.,  2001; Sugiyama et al., 2003). The HPV detection rates at this 
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anatomical site is very variable, probably due to differences in sample size, in the population 
studied and in the sensitivity of the techniques used. 
The presence of HPV in oral cancers suggests that HPV may play a similar role in 
transforming the oral epithelia. Persistent infection with high-risk types of HPV plays a 
critical role in the pathogenesis of cervical cancer, as well as OSCC. HPVs are 8-kb circular 
DNA viruses that specifically target the basal cells of the epithelial muscosa. The HPV 
family is comprised of more than 100 genotypes, classified in accordance with the type of 
epithelial cells infected and the ability to effect cellular transformation. The ability of HPV to 
transform epithelial cells is divided into high-risk and low-risk types. Low-risk types are 
associated with benign lesions such as warts, while infections with high-risk types progress 
to malignant lesions. The HPV genome is comprised of several early (E1 to E7) and late (L1 
and L2) genes, as well as a non-coding region, all of which play roles in viral replication, 
transcription, and carcinogenesis (Ragin et al., 2007). 
The primary risk factors for the majority of head and neck cancer worldwide are tobacco 
and alcohol consumption (Hennessey et al., 2009). In spite of these traditional risk factors, 
the HPV-positive HNSCC, in particular high-risk HPV type 16, appears more frequently 
than HPV-negative HNSCC in non-smokers and non-drinkers (Gillison et al., 2000; 
Hafkamp et al., 2003; Ritchie et al., 2003; Haraf et al., 1996). In case-control researches, the 
association between tobacco or alcohol use and the development of HPV-positive HNSCC 
was not found (D’Souza et al., 2007; Gillison et al., 2008). Furthermore, human 
papillomaviruses have recognized influence in the development of HNSCC in such sites 
as oropharynx, being considered as an independent risk factor (Schwartz et al., 1998; 
Gillison et al., 2000; Mork et al., 2001; Wiest et al., 2002; Herrero et al., 2003; Hobbs et al., 
2006; Ernster et al., 2007; Andrews et al., 2008). Nevertheless, there is controversy in the 
literature as to the combination of HPV infection with tobacco and/or alcohol increasing 
the risk of cancer. Schwartz et al. (1998) and Smith et al. (2004) showed an additive effect 
between oral HPV infection, tobacco or alcohol use, and oral cancer, but more researches 
are necessary to evaluate possible interactions among these exposures (Vidal & Gillison, 
2008). 
The two most prevalent HPV types in oral carcinomas are HPV 16 and 18, far exceeding the 
detection rate of all the other types (Snijders et al., 1996, 1997, Badaracco et al., 2000; 
Syrjänen and Syrjänen, 2000; Miller and Johnstone, 2001; Ringströmet al., 2002). 
Interestingly, the low-risk HPV types 6 and 11 can also be identified in some oral 
carcinomas, similar to laryngeal carcinomas (Yamaguchi et al., 1991; Fife et al., 1996; Chang 
et al., 2002). A study by Sisk et al. (2000) showed that the incidence of HPV in younger 
patients is not significantly different from older patients, suggesting a similar role for HPV 
in all age groups. 
Sexual contact has been associated to cervical cancer through high-risk mucosatropic 
HPVs (IACR, 1995), but the means by which HPV is transmitted to the upper airways are 
still unclear (Mannarini et al., 2009). Studies showed a rare oral HPV infection in newborn 
babies of infected mothers (Watts et al. 1998) and children prior to sexual activity (Koch et 
al., 1997) being the infections rate increased from the first sexual intercourse (Kellokoski et 
al., 1992). 
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Sexual behavior has an association with HPV-positive cancer in head and neck cancer, as 
observed by D’Souza et al. (2007) in a case-control study of 100 individuals with 
oropharyngeal cancer and 200 control persons, which found that the development of 
oropharyngeal cancer is linked with a high lifetime number of vaginal sex partners (≥ 26) 
and with a high lifetime number of oral sex partners (≥ 6). Gillison et al. (2008) found with a 
case-control study of 240 individuals with oropharyngeal cancer that the risk of developing 
an HPV-16-positive HNSCC increased with increasing numbers of oral sex partners. In 
addition, oral-anal contacts are very strongly associated with the risk of HPV-positive tumor 
(Rosenquist et al., 2005; Rajkumar et al., 2003). 
In a research, Rintala et al. (2006) observed the natural history of oral and genital HPV 
infection. The results showed that oral sex had no association to oral HPV infection; 
however, a persistent oral HPV infection of the spouse increased the risk of persistent oral 
HPV infection 10-fold in the other spouse. 
Although the relation of cannabis sativa with HPV infections of head and neck sites is unclear 
(Mannarini et al., 2009), such behavior has been proposed as a reason for increasing 
numbers of young patients with head and neck cancer (Báez, 2008). Gillison et al. (2008) 
observed a strong association between cannabis sativa use and HPV-16 – positive HNSCC, 
with a relation of increasing intensity and duration of use. 
Among the risk factors for HPV infection in head and neck tumors, there is the immuno-
suppression, as observed in human immunodeficiency virus (HIV)-positive cases 
(Adamopoulou et al., 2008). The genetic susceptibility is also an important risk factor to 
increase the risk of HPV infection, as noted in Fanconi anemia (Park et al., 2010). 
3.2 Epidemiology of head and neck cancer with HPV involvement 
3.2.1 Premalignant lesions 
According to Axell et al. (1996), premalignant lesions, or pre-cancer lesions, of the oral 
mucosa are epithelial changes more likely to undergo malignant transformation than 
normal tissue at other mucosal sites. There are two types of clinical premalignant lesions: 
white lesions (leukoplakia) and reddish lesions (erythroplakia) (Axell et al., 1996). These two 
terms are purely clinical, and have no association with the underlying histopathology 
(Syrjänen, 2005). 
3.2.1.1 Erythroplakia 
Erythroplakia lesions are defined as a bright red patches that cannot be diagnosed as any 
other lesions (Axell et al., 1996). There are few researches about erythroplakia lesions 
involving human papillomavirus in head and neck. Nielsen et al. (1996), in a case-control 
study with 49 patients with oral premalignant lesions, observed 10 cases of oral 
erythroplakia (1 man and 9 women). The presence of HPV was examined 
immunohistochemically, through DNA–DNA in situ hybridization and through PCR. The 
investigations revealed that HPV was found in 50.0% of the erythroplakias and 33.3% of 
erythroleucoplakias. The authors concluded that HPV may be an etiologic co-factor, because 
100% of patients who developed oral cancer within 4–12 years were all positive for HPV, 
with one being HPV-16-positive. This sample had few cases and a critical analysis of these 
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results is necessary. Further confirmatory data are needed before any conclusions can be 
drawn on the possible causal role of HPV in this disease (Syrjänen, 2005). 
 
 
 
Fig. 2. Erythroplakia in soft palate 
3.2.1.2 Leukoplakia 
Oral leukoplakia is considered as a premalignant lesion for the development of oral 
squamous cell carcinoma (OSCC) and several risk factors have been reported to contribute 
to this step-wise carcinogenesis, including human papillomavirus (HPV) (Yang et al., 
2009).  
Syrjänen (2005) observed in the literature 964 leukoplakia biopsies, of which 31.1% 
contained HPV DNA. The HPV types 6/11 were the most prevalent (55.8%), followed by 
HPV types 16/18 evidenced in 28.2% of the cases (Miller & Johnstone, 2001). 
However, Yang et al. (2009) analyzed, using PCR in paraffin sections, 167 patients with 
oral leukoplakia, including 12 who had malignant transformation from the pre-existing 
oral leukoplakia. The HPV prevalence in patients with oral leukoplakia was 
approximately 22.8%, and the most prevalent viral strain was HPV-18 (78.9%). This 
research also suggested that HPV in oral leukoplakia is not a prognostic indicator of 
malignant transformation.  
Ostwald et al. (2003) examined 72 oral leukoplakia for the presence of HPV 6/11, 16 and 18 
DNA through PCR/Southern blot hybridization. The HPV DNA was found in 16/72 
(22.2%) leukoplakias, and HPV 16 and 18 DNA were present in 12/72 (16.7%) leukoplakias, 
being 11.1% the detection rate of HPV 6/11. 
In a case-control study, the HPV presence was found in 62.5% of the verrucous leukoplakias, 
45.5% of the homogeneous leukoplakias and in 12.5% of the nodular leukoplakias (Nielsen 
et al., 1996). 
www.intechopen.com
Human Papillomavirus and Related Diseases  
– From Bench to Bedside – A Clinical Perspective 
 
204 
 
Fig. 3. Leukoplakia in buccal. 
3.2.2 Oral cavity and lips 
Clinical presentation of oral cancer is highly variable. On clinical examination, oral SCC 
lesions may be preceded by mucosal alterations with histologically detectable dysplastic 
changes. However, a malignancy involving a complex genetic process may also occur 
directly “de novo” without any pre-existing clinically detectable mucosal changes. All head 
and neck carcinomas tend to be diagnosed late because there is no pain until the late stages. 
Thus, the overall survival is only 40–50% (Johnson et al., 1991; Berrino et al., 1999; 
Franceschi et al., 2000). 
Studies that support a causal relationship between HPV and OSCC include: a consistent 
detection of HPV DNA in tumor specimens (Hansson et al., 2005); E6/E7 viral oncogene 
expression in oral lesions (Braakhuis et al., 2004); the requirement of oral carcinoma cell 
lines to express E6/E7, to maintain a malignant phenotype; and epidemiological data 
highlighting HPV infection as a risk factor for the development of OSCC (Ragin et al., 2007). 
At least three proteins (E5, E6, E7) coded by the high-risk HPVs, which are expressed 
throughout the viral life cycle, are considered oncogenic, due to their transforming and 
growth-stimulating properties. These proteins have the ability to deregulate tumor 
suppressor function by binding to and abrogating the functions of p21 (Tsai & Chen., 2003),  
p53 (Camus, 2007), and pRb (Huh et al.,2007) proteins, resulting in defects in apoptosis, 
DNA repair, cell cycle control, and eventually leading to cellular immortalization. 
Oliveira et al. (2009) showed that the presence of HPV DNA by PCR was detected in only 
29.5% of OSCC cases, 80.8% of which were identified for HPV 18. Although this 
investigation have detected only 29.5% of HR-HPV DNA in OSCC, it is possible that this 
virus contribute to the development of some case of this tumor. Furthermore, it seems that 
the immunohistochemical expression of p53 and bcl-2 and the presence of HPV DNA are 
independent events in OSCC. 
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Cancers involving the oral cavity account for 2–3% of all malignancies and the tongue is the 
subsite with the highest incidence of cancer in the oral cavity (Silverman Jr, 2001). The 
tongue may be the first site of exposure to viral microorganisms in the aerodigestive tract 
and oral tongue cancer could be susceptible to HPV exposure, directly or indirectly. The 
prevalence of HPV in oral tongue cancer is extremely diverse, ranging from 0% to 100% in 
the literature, and the prevalence of HPV in HNSCC is not uncommon (Bouda et al.,  2000, 
Gillison et al., 2001,  Matzow , 1998, Ringström , 2002). The markedly different reports of 
prevalence of HPV in oral tongue cancer may be due to: mixed samples with the 
oropharynx; methodological differences for detecting HPV, including less accurate methods; 
various tumour stages and racial and geographical differences between the studies. 
In a study made in the Republic of Korea for Lee et al. (2010), HPV prevalence in early oral 
tongue cancer was 36% (13/36). In the HPV-positive tumours, 11 cases (84.8%) were infected 
with HPV-16 and the others were infected with non-16 highrisk type and low-risk type HPV 
each and multiple infections were not found in these cases. 
Sugiyama et al. (2007) examined 66 oral squamous cell carcinomas (OSCCs) for human 
papillomavirus-16 (HPV-16) infection to evaluate its prognostic significance. Cox regression 
analysis of 5-year survival demonstrated that patients without nodal metastasis or with 
intratumoural HPV-16 showed better prognoses compared with each counterpart. In 
Kaplan-Meier survival analysis, nodal status but not HPV-16 status was statistically 
significant. The 5-year survival rate of HPV-16 positive patients without nodal metastasis 
(94%) was extremely high, compared with that of HPV-16 negative patients with nodal 
metastasis (25%). These results suggest that HPV-16 status as well as nodal status may 
provide prognostic significance in patients with OSCC. 
 
Fig. 4. Oral cancer in tongue. 
3.2.3 Pharynx 
3.2.3.1 Oropharynx 
The oropharynx is the predominant site where HPV-induced squamous cell carcinomas 
develop (Braakhuis et al., 2009). This region of interest for HPV infection comprises 
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predominantly the vallecula, walls of the oropharynx, and in particular the tonsils (Kreimer 
et al., 2005).  
In some countries, such as the United States and the Netherlands, the incidence of 
oropharyngeal cancer is increasing (Braakhuis et al., 2009; Ernster et al., 2007), and it 
represents an emerging public health problem (St Guily et al., 2011). One potential way to 
explain this increase would be to demonstrate an increasing prevalence of oncogenic HPV in 
palatine or lingual tonsil tissue over time (Ernster et al., 2009). 
Studies found a strong association between oropharynx cancers and HPV infection, with 
detection rates of 50% or more (Hammarstead et al., 2006; Klussmann et al., 2001; Venuti et al., 
2004; Paz et al., 1997). The biological explanation for why the prevalence of HPV is higher in 
tumors from the oropharynx compared with other sites in the head and neck remains unclear 
(Kreimer et al., 2005). However, it is possibly explained because of “specific virus-tissue 
interactions” (Kreimer et al., 2005) that allow a facilitated viral access to basal mucosal cells in 
the tonsillar crypts and an apparent predilection for this anatomic site for transformation by 
HPVs, analogous to the cervical transformation zone (Vidal & Gillison, 2008).   
In a systematic review of HNSCC biopsies that employed PCR-based methods to detect and 
genotype HPV, Kreimer et al. (2005) observed a HPV prevalence significantly higher in 
oropharyngeal squamous cell carcinomas (35.6% of 969) than in oral squamous cell 
carcinomas (23.5% of 2,642) or laryngeal squamous cell carcinomas (24.0% of 1,435). 
Furthermore, the human papillomavirus type 16 was found in a larger majority of HPV-
positive oropharyngeal squamous cell carcinomas (86.7%). However, the HPV18 infection 
was rare in HPV-positive oropharyngeal SCCs (2.8%) compared with other head and neck 
sites. Aside from HPV16 and HPV18, other oncogenic HPVs were rarely detected in 
oropharynx. This research also found geographic differences in HPV-positivity of 
oropharyngeal carcinomas possibly linked to differences in HPV exposure or variation in 
host susceptibility factors among countries. 
From a literature review worldwide, Syrjänen (2004) identified 422 tonsillar SCCs and 51% 
of these tumors contained HPV DNA.  The HPV 16 was the most frequent type, identified in 
84% of the 216 HPV DNA-positive tumors, but also the low-risk HPV types 6/11 DNA have 
been detected in 3% of the HPV-positive carcinomas, and the following HPV types have 
been detected in occasional tonsillar carcinomas: HPV 5, 12, 31, 35, and 59.  
In a research developed in France, the overall HPV prevalence was 57% in tonsil cancers, 
and was significantly higher in female than in male cases (28/35 versus 78/150 in tonsil 
cases). Among HPV positive samples, HPV 16 was found in 89% of tonsil cases, and all 
other HPV types had prevalence below 5% (St Guily et al., 2011). 
In Norway, a study with 137 patients about the prevalence of HPV with tonsillar carcinomas 
observed HPV infection in 52% of the tumors being the HPV-16 the most frequent subtype 
(87%). Furthermore, the study showed that the survival of the HPV-positive group was 
significantly better in males (Hannisdal et al., 2010). 
In Stockholm, 98 pretreatment biopsies of tonsillar squamous cell carcinoma were analyzed. 
The HPV DNA was present in 83 cases (85%) of the tonsillar SCC biopsies and 77 of these 
were HPV-16 positive. HPV-16 E6 and E7 RNA were found in 98% of 52 HPV-16 positive 
cases analyzed. In addition, the incidence rate of HPV-positive tumors almost doubled each 
decade between 1970 and 2007, in parallel with a decline of HPV-negative tumors. The 
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study suggested that the incidence of HPV-positive cancers is still increasing in Stockholm, 
and also an epidemic of a virus-induced carcinoma, with soon practically all tonsillar SCC 
being HPV positive, as in cervical cancer (Nasman et al., 2009). 
A study developed in the United States in the state of Colorado through PCR observed an 
increase of oropharyngeal cancer in males from 2.54 per 100,000 to 3.47 or 36.6%. Of the 72 
cases, 50 (69%) were positive for HPV subtype 16. The ratio of HPV-positive to HPV-
negative cases prior to 1995 was 0.72 (8:11), but it was 3.81 (42:11) afterwards. The survival 
was positively affected by HPV status, being 83% in the HPV-positive patients and 15% in 
the HPV-negative group (Ernster et al., 2007).  
A research in Puerto Rico evaluated through PCR 118 head and neck squamous cell 
carcinoma, and 16 cases were found in the oropharynx. Furthermore, in 52 patients, HPV16 
was detected, being 19% or 10 cases in oropharynx that had a slightly higher incidence of 
HPV16 DNA (Báez  et al., 2004). 
In Australia, a study involving 86 tonsil cancers analyzed the HPV status through PCR and 
immunohistochemistry. The HPV status could be established in 67 of the tumors, and 31 
(46%) of these were HPV-positive, predominantly (28/31) for HPV16 (Li et al., 2003).  
Overall, the percentage of HPV-positive oropharyngeal carcinomas varies among different 
reports, which is not only explained by the varying inclusion of tumors from different 
anatomic sublocations among studies (van Monsjou et al., 2010). Therefore, further 
standardized seroepidemiologic studies are important to answer some questions. 
3.2.3.2 Nasopharynx 
Nasopharyngeal carcinoma (NPC) is a tumor that arises in the epithelium surface of the 
posterior nasopharynx and shows a peculiar geographic and ethnic distribution (Parkin et 
al., 1997). Despite the strong association with Epstein-Barr virus (EBV), the human 
papillomavirus (HPV) has also been linked as a cofactor for the development of 
nasopharyngeal carcinoma  (Punwaney et al., 1999).  
Although NPC is rare in most populations, it is a leading form of cancer in a few well-
defined populations, including natives of southern China, Southeast Asia, the Arctic, and 
the Middle East/North Africa. Thus, the distinctive racial/ethnic and geographic 
distribution of NPC worldwide suggests that both environmental factors and genetic traits 
contribute to its development (Chang & Adami, 2006). 
In North Africa, 70 Moroccan patients with NPC were screened for EBV and HPV. The EBV 
was detected in all NPC tumors, whereas HPV DNA was revealed in 34% of cases (24/70). 
Molecular analysis showed that 20.8% (5/24) were infected with HPV31, and the remaining 
were infected with other oncogenic types (i.e., HPV59, 16, 18, 33, 35 and 45). The mean age 
of HPV-positive patients was 37.3, whereas the mean age of HPV-negative cases was 43.0 
years old. Nonetheless, the statistical analysis showed that there’s no association between 
sex or age and HPV infection. The study revealed that EBV is commonly associated with 
NPC in Moroccan patients and that NPC tumors from Moroccan patients harbor high-risk 
HPV genotypes (Laantri et al., 2011). 
In Iran, a retrospective study analyzed the prevalence of EBV and HPV infection subtypes 
6/11 and 16/18 in 20 patients with NPC. Thus, 16 cases were classified as undifferentiated 
carcinoma (WHO type III) and 4 as non-keratinizing SCC (WHO type II). About the HPV 
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infection, two of 20 NPC (10%) contained HPV 6/11 sequences and two of 20 NPC (10%) 
contained HPV 16/18 sequences, and combined EBV and HPV infection was detected in 3 of 
the 20 (15%) patients (Mirzamani et al., 2006). 
A research involving North Americans with NPC showed that five (5.6%) of 89 cases had 
nasopharyngeal carcinoma, all with non-keratinizing histology. Of the 5 patients with NPC, 
4 (80%) were HPV-positive for subtypes 16 (1 patient), 18 (2 patients), and 59 (1 patient). All 
4 cases were white North Americans with age ranging between 58-76 years old. Therefore, it 
suggests that HPV may be the etiologic factor in some EBV-negative, nonkeratinizing NPCs 
among whites (Maxwell et al., 2010). 
An investigation developed by Punwaney et al. (1999) with 30 patients (6 Caucasian 
Americans, 1 Chinese American, 14 and 9 patients from Korea and China, respectively) 
found in 7 (23%) HPV sequences. The human papillomavirus appears to be uncommonly 
(17%) associated with NPC in patients from the Far East and was detected more often (50%) 
in NPC from American Caucasian patients. There appears to be a broad profile in the 
relationship between HPV, EBV, and NPC histologic subtype. However, strong conclusions 
are not possible because of a low number of American Caucasian cases studied.  
In Hong Kong Chinese people, 16 of nasopharyngeal were examined for the presence of 
HPV 16 and 18 using PCR on paraffin-wax-embedded biopsy specimens. However, no DNA 
of either human papillomavirus subtype was detected. The number of cases in this series 
was small, and further studies are warranted using fresh biopsy material and including 
other viral subtypes (Dickens et al., 1992). 
Singhi et al. (2011) analyzed 45 carcinomas of the nasopharynx through 
immunohistochemistry and in situ hybridization for EBV and HPV. In this series, only 4 
cases (9%) were HPV-positive being all these specimens EBV-negative. The HPV was more 
likely to be detected in carcinomas from white patients than non-white patients (16% vs 0%), 
and in 3 HPV-positive patients, there was the finding of an extension into the oropharynx.  
Further studies are still required to associate the coexistence of EBV and HPV in the 
development of nasopharyngeal carcinomas (Mirzamani et al., 2006; Tyan et al., 1993). 
Moreover, epidemiology studies would also be of interest to determine whether the 
incidence of HPV-positive NPC is increasing in concert with the increased frequency of 
HPV-positive oropharyngeal cancers (Maxwell et al., 2010). 
3.2.3.3 Larynx and hypopharynx 
The larynx is among the most significant anatomic sites in terms of HPV involvement, 
exceeded in clinical importance perhaps only by the genital tract and skin infections 
(Syrjänen, 2005). However, the HPV role in anatomic sites in the upper aerodigestive tract 
such as the larynx is less clear (Herrero, 2003), and data on HPV involvement in 
preneoplastic and neoplastic lesions of the larynx and other locations are limited and 
conflicting (Gorgoulis et al., 1999).  
The hypopharynx comprises the postcricoid region, hypopharyngeal region of the 
aryepiglottic fold, and posterior wall of the hypopharynx (Kreimer et al., 2005). 
Unfortunately, there are few researches involving only hypopharynx in association with 
HPV presence in the literature. In this chapter, the hypopharynx and larynx were combined 
because of few reports observed in hypopharynx with HPV involvement and for the reason 
that some manuscripts aggregated these anatomical sites. Therefore, this group of diseases 
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was called ‘‘larynx cancers’’ or laryngeal squamous cell carcinomas (SCCs) in accordance to 
Kreimer et al. (2005).  
3.2.3.4 Larynx cancers 
Most malignancies in the larynx are squamous cell carcinomas (>90%). Similar to oral and 
pharyngeal cancers, multiple case series have reported prevalences of HPV DNA in 
laryngeal cancer (Herrero, 2003). Although the association and clinical significance of 
human papillomavirus (HPV) infections with a subset of head and neck cancers, particularly 
for oropharyngeal carcinoma, has recently been well documented, the involvement of HPV 
in laryngeal cancer has been inadequately evaluated (Torrente et al., 2011). 
In a systematic review worldwide comprising 1,435 cases (1,222 of larynx and 213 of 
hypopharynx cancers), the overall HPV prevalence was of 24% in laryngeal SCCs. The HPV 
was detected in 21.3%, 13.8%, and 38.2% of SCCs of the larynx from Europe, North America, 
and Asia, respectively. In addition, the HPV16 was the most common type detected in 
samples accounted for 69.2% of all HPV-positive laryngeal SCCs, followed by HPV18 
detected in 3.9% of cases (Kreimer et al., 2005). 
A study of Syrjänen & Syrjänen (2000) involving 1,252 cases had a detection rate of 25% for 
HPV DNA in 313 samples. Furthermore, the HPV 16 was the single most common HPV type 
detected in these lesions, with other high-risk types being occasionally reported. 
In the United States, 21 hypopharynx cases and 86 larynx cases were evaluated through 
PCR, Southern blot hybridization and in situ hybridization. Thus, the HPV positivity was 
identified in 10% of hypopharynx samples and 19% of larynx samples (Gillison et al., 2000). 
In Poland, the HPV 16 DNA presence was analyzed using PCR technique in 72 samples of 
laryngeal carcinoma. The human papillomavirus was detected in 26 (36.1%) of the 72 
patients. However, there was no statistically significant correlation HPV positivity and 
clinical-pathological features of the group analyzed (Morshed et al., 2005). 
In France, the human papillomavirus was detected in 5% in larynx squamous cell carcinoma, 
and no patient analyzed had p53 gene mutations in cancer cells (Fouret et al., 1997). 
In Belgium, the laryngeal squamous cell carcinomas were evaluated for the presence of HPV 
DNA through  E6/E7 type-specific PCR, and 75% of patients (44 out of 59) presented high-
risk HPV types with a high prevalence of HPV-16 (Duray et al., 2011). 
In the Puerto Rican population, of 118 head and neck squamous cell carcinoma evaluated 
through PCR, the larynx was the most common site affected (52 out of 118). Separately, the 
HPV 16 detected in larynx was 85.7% and 55.6% in hypopharynx. When aggregated, the 
hypopharynx and larynx showed 56% (29 cases) of all HPV16 DNA detected in the study 
(Báez  et al., 2004). 
In Northeast China, 102 patients with laryngeal squamous cell carcinomas were examined 
for HPV DNA. The HPV DNA was found in 60 cases (58.8%), being the HPV-16, -18, -6, -11, 
and -33 DNA detected in 30 cases, 22 cases, 25 cases, 2 cases and 1 case, respectively. 
Moreover, co-infection either with HPV-6 and -16 or with HPV-6 and -18 was detected in 20 
cases (33.3% of HPV DNA-positive cases) (Ma et al., 1998). 
A retrospective study examining early larynx malignancies from 38 patients detected a rate 
of 16% in HPV DNA, and the HPV types 16, 26, 31, 39, and 52 were identified. Although the 
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HPV-26 is related to uterine cervical cancer, the research found the first evidence of this 
subtype in a laryngeal carcinoma (Baumann et al., 2009). 
Although several researches support the HPV presence in hypopharynx/larynx cancer with 
prevalences ranging of 13.8% to 38.2% (Kreimer et al., 2005), Ribeiro et al. (2011) observed in 
78 fresh tissue biopsies a low prevalence of 3.8% in cases from Central Europe and Latin 
America. These wide variations in HPV prevalence which are reported may depend on the 
HPV diagnostic methodologies, especially in earlier studies (St Guily et al., 2010). 
Researches for the development of accurate, specific, and confirmatory methods for the 
detections of HPV in laryngeal squamous cell carcinoma are necessary, being standardized 
seroepidemiologic studies important to answer some questions. 
Table 2. summarizes some researches of head and neck lesions with HPV involvement. 
 
AUTHORS 
(YEAR) 
GEOGRAPHIC 
LOCATION 
METHOD* 
HPV 
TYPE**
POSITIVE/
CASES 
% 
O
R
A
L
 C
A
V
IT
Y
 A
N
D
 L
IP
 
Kreimer et al. 
(2005) 
Australia, Canada, 
China, Cuba, Finland, 
France, Germany, India, 
Ireland, Italy, Japan, 
Korea, Netherlands, 
Norway, Poland, Spain, 
Slovenia, Sudan, 
Sweden, Switzerland, 
Taiwan, United 
Kingdom, United States, 
Venezuela
PCR-based 
HPV testing 
methods 
HPV-16
423/ 
2,642 
16% 
Oliveira et al. 
(2009)
Brazil PCR HPV-18 21/88 23,9% 
Lee et al.
(2010)
Republic of Korea 
HPV genotyping 
chip and RT-PCR
HPV-16 11/36 30,6% 
O
R
O
P
H
A
R
Y
N
X
 
Kreimer et al. 
(2005) 
Australia, Canada, 
Cuba, Finland, France, 
Germany, India, 
Ireland, Italy, Japan, 
Netherlands, Norway, 
Poland, Spain, Slovenia, 
Sudan, Sweden, 
Switzerland, United 
States
PCR-based 
HPV testing 
methods 
HPV-16 299/969 30,9% 
St Guily et al. 
(2011) 
France 
INNO-LiPA HPV 
Genotypingextra 
test
HPV-16 94/185 50,8% 
Nasman et al. 
(2009) 
Stockholm PCR HPV-16 77/98 78,6% 
Ernster et al. 
(2007) 
United States PCR HPV-16 50/72 69,4% 
Li et al. 
(2003) 
Australia PCR and IHC HPV-16 28/67 41,8% 
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AUTHORS 
(YEAR) 
GEOGRAPHIC 
LOCATION 
METHOD* 
HPV 
TYPE**
POSITIVE/
CASES 
% 
Báez  et al. 
(2004) 
Puerto Rico PCR HPV-16 10/16 62,5% 
N
A
S
O
P
H
A
R
Y
N
X
 Laantri et al. 
(2011) 
Morocco PCR HPV-31 5/70 7,1% 
Mirzamani et 
al. (2006) 
Iran ISH 
HPV-
6/11; 
HPV-
16/18 
2/20; 
2/20 
10%; 
10% 
Dickens et al. 
(1992) 
Hong Kong PCR none 0/16 0% 
L
A
R
Y
N
X
 A
N
D
 H
Y
P
O
P
H
A
R
Y
N
X
 
Kreimer et al. 
(2005) 
Canada, Cuba, 
Denmark, Finland,  
France, Germany, 
Greece, India, Italy, 
Japan, Netherlands, 
Norway, Spain, 
Slovenia, Sweden, 
Switzerland, United 
Kingdom, United States
PCR-based 
HPV testing 
methods 
HPV-16 238/1,435 16,6% 
Morshed et 
al. (2005) 
Poland PCR HPV-16 26/72 36.1% 
Ma et al. 
(1998) 
Northeast China PCR, SB, and IHC HPV-16 30/102 29,4% 
E
R
Y
T
H
R
O
P
L
A
K
IA
 
D’Costa et al. 
(1998), 
Giovannelli et 
al. (2002), 
Syrjänen & 
Syrjänen 
(2000) 
India, Italy, ??? PCR, ??? HPV-16 9/32 28,1% 
L
E
U
K
O
P
L
A
K
IA
 
Ostwald et al. 
(2003) 
Germany PCR, SB 
HPV-
16/18 
12/72 16.7% 
*Abbreviations: PCR = Polymerase chain reaction, RT-PCR = Real Time PCR, IHC = 
Immunohistochemistry, SB = Southern Blotting, ISH = In situ hybridization. 
 **Most common HPV types found in studies. 
Table 2. Prevalence of HPV in lesions of the head and neck. 
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4. Conclusion 
The present review showed heterogeneous prevalence between different anatomical sites in 
HNSCC with HPV involvement around the world. These results must be interpreted with 
caution because most researches conducted for data on HPV and HNSCC have been, with 
rare exception, small (<100 cases). The methods employed for case identification have often 
been unclear, and it is difficult to differentiate studies that enrolled consecutive patients 
from studies that used alternative inclusion criteria. Moreover, poor quality of some biopsy 
specimens may also have affected the prevalence estimates with some false-negative 
findings (Kreimer et al., 2005).  
Further standardized seroepidemiologic studies are important to answer some questions, 
among them the impact of HPV vaccination on HNSCC. Thus, epidemiology studies are 
interesting to determine whether the incidence of HPV-positive is increasing, mainly in sites 
frequently affected such as oropharynx, in particular the tonsils. 
In conclusion, with a clear understanding of the prevalence of oncogenic HPV in specific 
populations, an estimate of the progression rate from HPV infection to HPV-positive 
carcinoma may be derived. This effort could help guide screening and prevention strategies 
in the future (Ernster et al., 2009), such as the development of screening programs, new 
therapeutic approaches and specific methods of prevention, especially in high incidence 
areas (Laantri et al., 2011). 
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